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en inglés. En 57.1% de los estudios, CVRS era un resultado secundario. Tres estudios 
fueron ﬁnanciados por laboratorios farmacéuticos. De los 14 estudios, 4 eran trans-
versales, 4 pre-post, 3 de cohortes y 3 ciegos controlados aleatorizados. En cuanto a 
la calidad del reporte, 64.3% de los estudios utilizaban un instrumento previamente 
validado. La mayoría de los estudios (42.9%) tenían un tamaño de muestra pequeño. 
En sólo 7.1% de los artículos se indicó el tratamiento de los datos perdidos y en 28.6% 
de los artículos se justiﬁcó la selección del instrumento utilizado. CONCLUSIONES: 
Existen pocos estudios publicados que evalúan calidad de vida en Venezuela. La 
mayoría de los estudios utilizan instrumentos diseñados y validados previamente. 
La calidad de los reportes de los estudios de calidad de vida en Venezuela debe 
mejorarse.
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METHODS: FOR ACHIEVING AND MAINTAINING ADEQUATE STUDY 
SUBJECT PARTICIPATION FOR A MULTI-SITE TIME-SERIES TRIAL
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OBJECTIVES: We sought to collect data from a national sample of adults in the 
United States seeking opioid dependence treatment in an outpatient setting. METHODS: 
From among a pool of several thousand physicians listed on a national registry, 
we secured agreements with more than 450 practices to invite their patients to join 
the study. Within three months, we successfully enrolled more than 2000 patients 
through their private physicians into the study. Subjects were required to complete a 
10–15 minute baseline telephonic interview and four additional 15–30 minute tele-
phonic interviews throughout the six month study. A variety of methods were used 
to maximize study enrollment and to retain subjects over the course of six months. 
Coordination of multiple patient and physician touch points was required. Not only 
were physicians asked to attend training and distribute study materials to patients, 
they were also asked to collect informed consent forms from patients. Because inclusion 
criteria dictated that patients must be new to treatment for opioid dependence, 
collection of baseline data had to coincide with treatment start. It was critical that 
any patients interested in joining the study and who provided informed consent be 
contacted immediately so that baseline data could be gathered. Techniques for patient 
engagement included remuneration for completion of each telephonic survey in addition 
to an incentive for enrollment. Baseline and follow-up interviews were scheduled 
according to subjects’ preferences. Patients also received study updates in the mail and 
through their personal physicians. RESULTS: Over the course of 6 months, the subject 
retention rate is at least 70%. We attribute this to a number of strategies, especially 
an efﬁcient study enrollment process, well-managed study administration, and consis-
tent communications with both patients and physicians. CONCLUSIONS: Researchers 
recruiting subjects from a general, treatment-seeking population can achieve sufﬁcient 
study retention by employing these straightforward methods.
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OBJECTIVES: The Canadian Psychiatric Association (CPA) treatment guidelines for 
generalized anxiety disorder (GAD) were developed using evidence-based criteria. CPA 
recommends: selective serotonin reuptake inhibitors (SSRIs) or serotonin norepineph-
rine reuptake inhibitors (SNRIs) as 1st line; benzodiazepines, bupropion, buspirone, 
pregabalin, and imipramine as 2nd line; and hyroxyzine, mirtazapine, trazadone as 
3rd line treatments including adjunctive olanzapine or risperidone for treatment-resis-
tant patients. A comprehensive quantitative synthesis of guideline-recommended drug 
therapies for GAD has not been located. The objective of the study was to quantify 
the rates of clinical outcomes of CPA guideline-recommended pharmacotherapies by 
line treatment. METHODS: Evidence from randomized clinical trials cited by the CPA 
and (original research) from meta-analytic evidence were included for review. Pooled 
analyses, duplicates, inappropriate condition, and studies with non-extractable data 
were excluded. Response, remission rates, and baseline, endpoint or mean reductions 
scores of the Hamilton Rating Scale for Anxiety (HAM-A) were extracted. Review 
Manager-5 software (Cochrane Collaboration 2008), with ﬁxed effects model using 
inverse variance weighting, was used to pool results. RESULTS: First line: 36 studies 
included, 21 excluded [pooled-analysis(4) duplicate(14), non-extractable(1), not pub-
lished(1); inappropriate condition(1)], 2nd line: 67 included, 34 excluded [pooled-
analysis(2) duplicate(30) non-extractable(2)], 3rd line: 7 studies included, 0 excluded. 
Mean HAM-A at baseline for 1st line: 24.8 (SD  1.94, N  2594), 2nd line: 25.7 
(SD  2.08, N  2592), 3rd line: 23.4 (SD  3.54, N  274). Mean HAM-A score 
reductions were: 1st line: 13.48 [CI95% 14.33, 12.63, N  1990], 2nd line: 12.19 
[CI95% 12.38, 12.00, N  2046], 3rd line: 12.31 [CI95% 12.96, 11.67, N  
238]. Summary remission rates were: 1st line: 39.7% [CI95% 35.2–44.1%, N  1502], 
2nd line: no pooled results, 3rd line: 35.7% [CI95% 23.1–48.2%, N  56]. Summary 
response rates were 1st line: 67.7% [CI95% 64.1–71.4%, N  2311], 2nd line: 54.5% 
[CI95% 48.0–61.1%, N  1409], 3rd line: 54.9% [CI95% 39.7–70.2%, N  242]. 
CONCLUSIONS: Summary results overlapped substantially; no statistical conclusion 
could be drawn as to which line of therapy was clinically superior.
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OBJECTIVES: We are proposing a research project aimed at better understanding the 
factors associated with speciﬁc disease states associated with schizophrenia. 
METHODS: The model was based on data from RAMQ and Med-Echo databases. 
A total of 12,754 newly diagnosed patients with schizophrenia patients were identiﬁed 
between 1998 and 2006, aged between 0 and 60. Six discrete disease states were 
deﬁned within the model (ﬁrst episode—FE, low dependency state—LDS, high depen-
dency state—HDS, Stable, Well and Death) and patients’ movements between these 
disease states enabled 17 risks to be identiﬁed. To evaluate factors associated to the 
risk of being in each disease state, we constructed 6 risk functions based on Cox pro-
portional hazard analysis for competing risks. The risk factors were modeled including 
age, gender, social assistance status, severity of schizophrenia, depression, anxiolytic 
drugs use and other mental disorders. RESULTS: After the FE of schizophrenia, 
69.8% of patients transitioned to LDS, 11.2% to HDS, 1% to the death state and 
18% into the Well state. Being male (HR: 0.93, 95% CI: 0.89–0.97) or older (HR: 
0.94, 95% CI: 0.91–0.96) was associated with a decreasing risk of moving to LDS 
after being FE. In contrast, being on social assistance, depressed, using anxiolytic drugs 
or being diagnosed with other mental disorders were associated with an increased risk 
of being in a LDS after a FE, ranging from 1.11 to 1.55 folds. The factors associated 
with the risk of being in HDS or Death state after a FE were also estimated.CONCLU-
SIONS: Based on these risk functions, we estimate individual transition probabilities 
that will be used in the ﬁrst Canadian model of schizophrenia incorporating transition 
probabilities adjusted for individual risk factors proﬁles using Canadian data.
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OBJECTIVES: Practice guidelines for treatment of opioid dependence released in Brazil 
recommend psychosocial treatment such as education and cognitive behavioral therapy 
as a core component of an overall treatment strategy. The purpose of this study was 
to investigate outcome differences between individuals in outpatient treatment for 
opioid dependence who received medication replacement therapy in conjunction with 
a formal psychosocial support program compared with those who received medication 
replacement therapy alone. In particular, we wished to understand whether or not and 
the extent to which adjunctive psychosocial support contributes to reducing early 
treatment failure for opioid dependence. METHODS: A quasi-experimental design 
was employed to randomly assign patients seeking treatment for opioid dependence 
to cases (standard treatment plus psychosocial support program) or controls (standard 
care alone). Data sources included patient self-report and administrative health care 
utilization claims. Collection of baseline measures coincided with treatment start with 
subsequent follow-up measures gathered at 1, 2, 3, and 6 months post baseline. More 
than 1500 subjects across the United States participated in the study. Primary endpoints 
include compliance and adherence to opioid dependence treatment, health care service 
utilization, psychosocial functioning, and addiction symptoms. RESULTS: Compared 
to controls, patients in outpatient treatment for opioid dependence who received 
additional patient support services like addiction education, treatment information, 
and assistance with locating other recovery resources, were less likely to experience 
early treatment withdrawal. CONCLUSIONS: This study demonstrates that when 
offered in conjunction with medication replacement therapy for opioid dependence, a 
formal psychosocial patient support program leads to longer periods of treatment 
retention and lower rates of relapse. In countries like Brazil where ofﬁce-based opioid 
replacement therapy is the ﬁrst-line treatment approach, additional patient support 
services can help reduce recurring relapse. This study has broad implications for com-
munities affected by the morbidity and mortality associated with opioid abuse.
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OBJECTIVES: Atypical antipsychotic medications have been shown to increase dia-
betes and CHD risk in patients by exacerbating lipid, weight, and glucose risk factors 
comprising the metabolic syndrome. We studied in a cost-consequence analysis the 
events and costs associated with the use of olanzapine versus aripiprazole from a 
double blind, 16 week randomized trial of schizophrenia patients. METHODS: A total 
of 173 overweight patients (body mass index „d 27 kglm2) with schizophrenia or 
schizoaffective disorder (previously treated with olanzapina) were randomized to 
treatment with aripiprazole or continued olanzapine monotherapy for 16-weeks 
